Amia Capital LLP Argenx Se Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$248.13 - $308.36 $1.26 Million - $1.57 Million	-5,077 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $51,506 - $65,129	-239 Reduced 4.5%	5,077 $1.33 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $371,997 - $679,309	-2,919 Reduced 35.45%	5,316 $1.2 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $194,261 - $294,935	-1,785 Reduced 17.81%	8,235 $1.09 Million
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $1.07 Million - $1.65 Million	10,020 New	10,020 $1.61 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.